News
06-02-2011, 10:50 PM
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."
More... (http://www.news-medical.net/news/20110603/Syndax-receives-US-patent-for-entinostat-to-treat-metastatic-cancers.aspx)
More... (http://www.news-medical.net/news/20110603/Syndax-receives-US-patent-for-entinostat-to-treat-metastatic-cancers.aspx)